Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study
Conclusions
Long-term, extended dosing of DA maintained Hb concentrations in patients already treated with an ESA and corrected and maintained Hb in ESA-naïve patients. (Source: Nephrology Dialysis Transplantation)
Source: Nephrology Dialysis Transplantation - December 7, 2016 Category: Urology & Nephrology Authors: Galle, J.-C., Addison, J., Suranyi, M. G., Claes, K., Di Giulio, S., Guerin, A., Herlitz, H., Kiss, I., Farouk, M., Manamley, N., Wirnsberger, G., Winearls, C. Tags: Chronic Kidney Disease Source Type: research
Efficacy and safety of darbepoetin alfa initiated at hemoglobin ≤10 g/dL in patients with stage IV cancer and chemotherapy‐induced anemia
Abstract
Data on efficacy and safety of darbepoetin alfa (DA) administered at hemoglobin (Hb) ≤10 g/dL are limited. In this analysis, we examined DA's efficacy and safety in patients with Stage IV cancers and chemotherapy‐induced anemia (CIA) initiated on DA at Hb ≤10 g/dL. Data for patients with Stage IV cancers and CIA and who initiated DA at Hb ≤10 g/dL were extracted from three phase 3 trials identified in a central database of Amgen‐sponsored DA studies in CIA. Efficacy outcomes were assessed by achievement of Hb increases of ≥1 g/dL and ≥2 g/dL and red blood cell (RBC) or whole blood transfusion re...
Source: Cancer Medicine - November 22, 2016 Category: Cancer & Oncology Authors: Ralph V. Boccia, David H. Henry, Laura Belton, Chet Bohac, Hassan H. Ghazal Tags: Original Research Source Type: research
Initiation of darbepoetin for management of anemia in non-dialysis-dependent patients with chronic kidney disease.
In this study, 36 patients (21 female, 15 male) were enrolled with a mean age of 46.4 ± 20.12 years. About 56% of the patients (n = 20) received darbepoetin alfa 40 μg Q2W for more than three months and 36% (n = 13) were on once-monthly doses, whereas the other 8% (n = 3) were on variable doses ranging from 20 to 60 μg every two weeks. More than 80% of the patients were converted from short-acting EPO to darbepoetin corresponding to a conversion ratio of 672.2 IU:1 μg (standard deviation = 488.5). Hb levels ≥10 g/dL were maintained in 77.78% of the patients. The safety profile of darbepoetin alfa in this study was re...
Source: Saudi Journal of Kidney Diseases and Transplantation - October 31, 2016 Category: Urology & Nephrology Authors: Al Raisi F, Al Salmi I, Kamble P, Al Shehri M, Shaheen FA Tags: Saudi J Kidney Dis Transpl Source Type: research
Mass spectrometric characterisation of darbepoetin alfa biosimilars with C ‐terminal arginine residues
In this study, a mass spectrometric characterisation of NESP biosimilar products is demonstrated. The study comprises a time‐of‐flight mass spectrometry characterisation for the asialo‐NESPs after sialidase digestion and primary structure characterisation using bottom‐up analysis after endoproteinase Glu‐C digestion of the core protein. The study revealed that there was a wide range of glycoforms spaced by 365 Da intervals, namely, HexHexNAc units, which indicated that NESP biosimilars likely contained more N‐acetyllactosamine units in their molecules. The bottom‐up analysis also showed that the NESP biosim...
Source: Drug Testing and Analysis - September 30, 2016 Category: Drugs & Pharmacology Authors: Masato Okano, Mitsuhiko Sato, Shinji Kageyama Tags: Research article Source Type: research
C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
Conclusions Elevated baseline CRP levels are common in type 2 diabetic patients with anemia and CKD and are associated with the future development of ESRD and the composite of death or ESRD. (Source: American Journal of Kidney Diseases)
Source: American Journal of Kidney Diseases - September 16, 2016 Category: Urology & Nephrology Source Type: research
Polycythemia and high levels of erythropoietin in blood and brain blunt the hypercapnic ventilatory response in adult mice
Changes in arterial Po2, Pco2, and pH are the strongest stimuli sensed by peripheral and central chemoreceptors to adjust ventilation to the metabolic demand. Erythropoietin (Epo), the main regulator of red blood cell production, increases the hypoxic ventilatory response, an effect attributed to the presence of Epo receptors in both carotid bodies and key brainstem structures involved in integration of peripheral inputs and control of breathing. However, it is not known whether Epo also has an effect on the hypercapnic chemoreflex. In a first attempt to answer this question, we tested the hypothesis that Epo alters the ve...
Source: AJP: Regulatory, Integrative and Comparative Physiology - May 14, 2016 Category: Physiology Authors: Menuet, C., Khemiri, H., de la Poëze d'Harambure, T., Gestreau, C. Tags: Respiration Source Type: research
Sp326 * comparing the efficacy of continuous erythropoietin receptor activator and darbepoetin alfa treatments in japanese patients with chronic kidney disease during the predialysis period: a propensity-matched analysis
(Source: Nephrology Dialysis Transplantation)
Source: Nephrology Dialysis Transplantation - May 13, 2016 Category: Urology & Nephrology Authors: Koibuchi, K., Aoki, T., Arai, T., Miyagi, M., Aikawa, A., Sakai, K. Tags: CHRONIC KIDNEY DISEASE ANAEMIA Source Type: research
Sp554 * low levels of serum ferritin with moderate level of transferrin saturation maintains adequate anemia control in hemodialysis patients treated with darbepoetin alfa
(Source: Nephrology Dialysis Transplantation)
Source: Nephrology Dialysis Transplantation - May 13, 2016 Category: Urology & Nephrology Authors: Ogawa, C., Tsuchiya, K., Kanda, F., Maeda, K. Tags: DIALYSIS. ANAEMIA Source Type: research
Preschool Assessment of Preterm Infants Treated With Darbepoetin and Erythropoietin
CONCLUSIONS:
ESA-treated infants had better cognitive outcomes and less developmental impairment at 3.5 to 4 years of age compared with placebo-treated infants. ESAs show promise in improving long-term cognitive outcomes of infants born prematurely. (Source: PEDIATRICS)
Source: PEDIATRICS - May 11, 2016 Category: Pediatrics Authors: Ohls, R. K., Cannon, D. C., Phillips, J., Caprihan, A., Patel, S., Winter, S., Steffen, M., Yeo, R. A., Campbell, R., Wiedmeier, S., Baker, S., Gonzales, S., Lowe, J. Tags: Developmental/Behavioral Pediatrics, Fetus/Newborn Infant, Neonatology Article Source Type: research
Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) [Kidney in Cardiovascular Disease]
Conclusions
In patients with chronic kidney disease, diabetes, and anemia, a history of CAD is an independent predictor of progression to dialysis. In patients with diabetic nephropathy, a history of CAD contributes important prognostic information to traditional risk factors for worsening renal disease. (Source: JAHA:Journal of the American Heart Association)
Source: JAHA:Journal of the American Heart Association - April 22, 2016 Category: Cardiology Authors: Sabe, M. A., Claggett, B., Burdmann, E. A., Desai, A. S., Ivanovich, P., Kewalramani, R., Lewis, E. F., McMurray, J. J. V., Olson, K. A., Parfrey, P., Solomon, S. D., Pfeffer, M. A. Tags: Nephrology and Kidney, Diabetes, Type 2, Coronary Artery Disease Kidney in Cardiovascular Disease Source Type: research
Polycythemia and high levels of erythropoietin in blood and brain blunt the hypercapnic ventilatory response in adult mice.
Abstract
Changes in arterial Po2, Pco2 and pH are the strongest stimuli sensed by peripheral and central chemoreceptors to adjust ventilation to the metabolic demand. Erythropoietin (Epo), the main regulator of red blood cell production, increases the hypoxic ventilatory response, an effect attributed to the presence of Epo receptors in both carotid bodies and key brainstem structures involved in integration of peripheral inputs and control of breathing. However, it is not known whether Epo also has an effect on the hypercapnic chemoreflex. In a first attempt to answer this question, we tested the hypothes...
Source: American Journal of Physiology. Regulatory, Integrative and Comparative Physiology - March 2, 2016 Category: Physiology Authors: Menuet C, Khemiri H, De la Poëze d'Harambure T, Gestreau C Tags: Am J Physiol Regul Integr Comp Physiol Source Type: research
Preschool Assessment of Preterm Infants Treated With Darbepoetin and Erythropoietin
CONCLUSIONS:
ESA-treated infants had better cognitive outcomes and less developmental impairment at 3.5 to 4 years of age compared with placebo-treated infants. ESAs show promise in improving long-term cognitive outcomes of infants born prematurely. (Source: PEDIATRICS)
Source: PEDIATRICS - March 1, 2016 Category: Pediatrics Authors: Ohls, R. K., Cannon, D. C., Phillips, J., Caprihan, A., Patel, S., Winter, S., Steffen, M., Yeo, R. A., Campbell, R., Wiedmeier, S., Baker, S., Gonzales, S., Lowe, J. Tags: Developmental/Behavioral Pediatrics, Fetus/Newborn Infant, Neonatology Article Source Type: research
Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study
Conclusions
No new safety signals for DA were identified in children receiving DA for CKD anemia for ≤2 years. Based on Hb concentrations and transfusion requirements, DA was effective at managing anemia in these patients. (Source: Pediatric Nephrology)
Source: Pediatric Nephrology - February 18, 2016 Category: Urology & Nephrology Source Type: research
Time savings of weekly versus three-times-per-week administration of erythropoiesis stimulating agents in United States dialysis patients.
CONCLUSIONS: Switching from TIW EPO to QW DPO can result in time savings due to fewer administrations and provide opportunities to redirect nurse time towards activities aimed at improving patient care.
PMID: 26583202 [PubMed - in process] (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - February 18, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research
Switch From Epoetin Beta to Darbepoetin Alfa Treatment of Anemia in Taiwanese Hemodialysis Patients: Dose Equivalence by Hemoglobin Stratification
In conclusion, the conversion ratio in the present study was higher than 1 µg: 200 IU for darbepoetin alfa: epoetin for treating anemia in Taiwanese HD patients. (Source: Therapeutic Apheresis and Dialysis)
Source: Therapeutic Apheresis and Dialysis - January 31, 2016 Category: Hematology Authors: Shang‐Chih Liao, Cheng‐Chieh Hung, Chien‐Te Lee, Chih‐Hsiung Lee, Chin‐Chan Lee, Chun‐Liang Lin, Chiao‐Yin Sun, Ben‐Chung Cheng, Chih‐Chao Yang, Chien‐Hsing Wu, Jin‐Bor Chen Tags: Original Article Source Type: research
